7 drugmakers in the headlines

The following drug companies made headlines in the past week.

1. Bella Pharmaceuticals voluntarily recalls all lots of unexpired sterile drug products
Bella Pharmaceuticals on Aug. 18 issued a voluntary recall of its unexpired sterile drug products due to a lack of sterility assurance.

2. Patients brace for price of Novartis' 'breakthrough' leukemia drug
Patients across the globe are bracing themselves for the price of CTL019, a new leukemia drug deemed a "breakthrough" by physicians.

3. Samsung widens stake in prescription drug market through partnership with Takeda Pharma

Tech-giant Samsung will widen its stake in the prescription drug market by producing novel drugs in partnership with Japan's Takeda Pharmaceutical Co.

4. US Bioservices to pay $13.4M to resolve kickback suit
US Bioservices Corp., a specialty pharmacy unit of AmerisourceBergen, agreed to pay $13.4 million to settle allegations that it pushed patients to refill prescriptions for Novartis AG's iron overload drug, Exjade, in exchange for kickbacks.

5. Centurion Labs recalls cold medicine over possible bacterial contamination
Centurion Labs recalled its Ninjacof and Ninjacof A cold medicine over potential bacterial contamination.

6. Gilead to acquire Kite Pharma for nearly $12B
Gilead Sciences on Monday agreed to purchase Kite Pharma for $11.9 million.

7. Novartis builds study on Apple ResearchKit to investigate multiple sclerosis
Basel, Switzerland-based pharmaceutical company Novartis and Seattle-based research nonprofit Sage Bionetworks initiated a large-scale study on multiple sclerosis using the Apple ResearchKit software framework Aug. 21.

More articles on supply chain:

Blood supplier expects shortages in Texas amid Hurricane Harvey
AI could help keep medications safe, says Xavier Health director
FDA approves treatment for Parkinson's drug side effect

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars